Positive Results in AD04 Study for Alcohol Use Disorder
Adial Pharmaceuticals completed a pharmacokinetic study of AD04, a selective serotonin-3 receptor antagonist for Alcohol Use Disorder (AUD), and...
eClinical Tech News
Cardiovascular Devices Market to Hit $110B by 2029
The global cardiovascular devices market, valued at US$72.83 billion in 2023, is projected to reach US$110.39 billion by 2029,...
Targeted Alpha Therapy Clinical Trials: An Overview
Over 20 alpha therapies are currently in clinical trials, marking a significant advancement in targeted cancer treatment. These therapies...
Cebranopadol Shows Low Abuse Potential in Clinical Trial
Tris Pharma announced positive clinical data from its intranasal human abuse potential (HAP) study of cebranopadol. The study demonstrated...
Silexion Shows Strong Tumor Reduction in Pancreatic Cancer Models
Silexion Therapeutics announced positive preclinical data for SIL-204, its RNAi therapeutic candidate targeting KRAS-driven cancers. The data validates systemic...
SAB Bio Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB Bio announced positive topline data from a Phase 1 trial of SAB-142, a human anti-thymocyte immunoglobulin being developed...
FDA Grants Cartesian Special Protocol for Phase 3 Trial in Myasthenia Gravis
Cartesian Therapeutics (NASDAQ: RNAC) received FDA approval under the Special Protocol Assessment (SPA) process for the Phase 3 AURORA...
Adagene Announces Updated Data From Phase 1b/2 Study of Muza in Colorectal Cancer at ASCO GI
Adagene Inc. announced positive updated clinical data for ADG126 (muzastotug), an anti-CTLA-4 SAFEbody® drug, combined with pembrolizumab in a...
Ocugen’s OCU500 Inhaled COVID-19 Vaccine Enters Phase 1 Trial
Ocugen has received FDA approval to begin a Phase 1 clinical trial for OCU500, an inhaled and nasal spray...
Elevated Therapeutics Post-Hoc Analysis of Etiology Impact on HCC Survival
Elevar Therapeutics announced positive results from a post-hoc analysis of the CARES-310 study, showing that camrelizumab plus rivoceranib provides...